Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Evaluating the impact of non-pharmaceutical interventions for SARS-CoV-2 on a global scale

Rachel Esra, Lise Jamieson, Matthew P. Fox, Daniel Letswalo, Nkosinathi Ngcobo, Sithabile Mngadi, Janne Estill, Gesine Meyer-Rath, Olivia Keiser
doi: https://doi.org/10.1101/2020.07.30.20164939
Rachel Esra
1Division of Infectious Diseases and Mathematical Modelling, Institute of Global Health, Faculty of medicine; University of Geneva, Geneva, Switzerland,
2Health Economics and Epidemiology Research Office (HE2RO), Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rachel.esra@unige.ch
Lise Jamieson
2Health Economics and Epidemiology Research Office (HE2RO), Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rachel.esra@unige.ch
Matthew P. Fox
2Health Economics and Epidemiology Research Office (HE2RO), Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa,
3Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Letswalo
2Health Economics and Epidemiology Research Office (HE2RO), Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nkosinathi Ngcobo
2Health Economics and Epidemiology Research Office (HE2RO), Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sithabile Mngadi
2Health Economics and Epidemiology Research Office (HE2RO), Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janne Estill
1Division of Infectious Diseases and Mathematical Modelling, Institute of Global Health, Faculty of medicine; University of Geneva, Geneva, Switzerland,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gesine Meyer-Rath
2Health Economics and Epidemiology Research Office (HE2RO), Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa,
3Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olivia Keiser
1Division of Infectious Diseases and Mathematical Modelling, Institute of Global Health, Faculty of medicine; University of Geneva, Geneva, Switzerland,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

In the absence of a viable pharmaceutical intervention for SARS-CoV-2, governments have implemented a range of non-pharmaceutical interventions (NPIs) to curb the spread of infection of the virus and the disease caused by the virus, now known as COVID-19. Given the associated social and economic costs, it is critical to enumerate the individual impacts of NPIs to aid in decision-making moving forward. We used globally reported SARS-CoV-2 cases to fit a Bayesian model framework to estimate transmission associated with NPIs in 26 countries and 34 US states. Using a mixed effects model with country level random effects, we compared the relative impact of other NPIs to national-level household confinement measures and evaluated the impact of NPIs on the global trajectory of the COVID-19 pandemic over time. We observed heterogeneous impacts of the easing of restrictions and estimated an overall reduction in infection of 23% (95% CI: 18-27%) associated with household confinement, 10% (95% CI: 1-18%) with limits on gatherings, 12% (95% CI: 5-19%) with school closures and 17% (95% CI: 6-28%) with mask policies. We estimated a 12% (95% CI: 9-15%) reduction in transmission associated with NPIs overall. The implementation of NPIs have substantially reduced acceleration of COVID-19. At this early time point, we cannot determine the impact of the easing of restrictions and there is a need for continual assessment of context specific effectiveness of NPIs as more data become available.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Role of the funding source: Rachel Esra is supported in part by the European Union's Horizon 2020 research and innovation programme and the Swiss Excellence Foreign Scholar Grant. Olivia Keiser is supported by the Swiss National Science Foundation Grants 163878 and 196270.This study has additionally been made possible by the generous support of the American People and the President's Emergency Plan for AIDS Relief (PEPFAR) through USAID under the terms of Cooperative Agreement 72067419CA00004 to HE2RO. The contents are the responsibility of the authors and do not necessarily reflect the views of PEPFAR, USAID or the United States Government.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This research did not involve human or animal subjects, and ethical approval was therefore not required

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Source code is available at https://github.com/epiforecasts/covid, unless otherwise noted.

https://gitlab.com/igh-idmm-public/covid-19/covid19_npi_globalrt_estimations

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted August 05, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Evaluating the impact of non-pharmaceutical interventions for SARS-CoV-2 on a global scale
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Evaluating the impact of non-pharmaceutical interventions for SARS-CoV-2 on a global scale
Rachel Esra, Lise Jamieson, Matthew P. Fox, Daniel Letswalo, Nkosinathi Ngcobo, Sithabile Mngadi, Janne Estill, Gesine Meyer-Rath, Olivia Keiser
medRxiv 2020.07.30.20164939; doi: https://doi.org/10.1101/2020.07.30.20164939
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Evaluating the impact of non-pharmaceutical interventions for SARS-CoV-2 on a global scale
Rachel Esra, Lise Jamieson, Matthew P. Fox, Daniel Letswalo, Nkosinathi Ngcobo, Sithabile Mngadi, Janne Estill, Gesine Meyer-Rath, Olivia Keiser
medRxiv 2020.07.30.20164939; doi: https://doi.org/10.1101/2020.07.30.20164939

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (76)
  • Allergy and Immunology (202)
  • Anesthesia (55)
  • Cardiovascular Medicine (497)
  • Dentistry and Oral Medicine (91)
  • Dermatology (57)
  • Emergency Medicine (170)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (220)
  • Epidemiology (5771)
  • Forensic Medicine (3)
  • Gastroenterology (223)
  • Genetic and Genomic Medicine (888)
  • Geriatric Medicine (89)
  • Health Economics (234)
  • Health Informatics (777)
  • Health Policy (401)
  • Health Systems and Quality Improvement (259)
  • Hematology (108)
  • HIV/AIDS (188)
  • Infectious Diseases (except HIV/AIDS) (6606)
  • Intensive Care and Critical Care Medicine (398)
  • Medical Education (120)
  • Medical Ethics (29)
  • Nephrology (94)
  • Neurology (863)
  • Nursing (46)
  • Nutrition (145)
  • Obstetrics and Gynecology (166)
  • Occupational and Environmental Health (268)
  • Oncology (521)
  • Ophthalmology (169)
  • Orthopedics (44)
  • Otolaryngology (108)
  • Pain Medicine (49)
  • Palliative Medicine (22)
  • Pathology (150)
  • Pediatrics (258)
  • Pharmacology and Therapeutics (147)
  • Primary Care Research (116)
  • Psychiatry and Clinical Psychology (998)
  • Public and Global Health (2271)
  • Radiology and Imaging (381)
  • Rehabilitation Medicine and Physical Therapy (176)
  • Respiratory Medicine (315)
  • Rheumatology (111)
  • Sexual and Reproductive Health (84)
  • Sports Medicine (83)
  • Surgery (118)
  • Toxicology (25)
  • Transplantation (35)
  • Urology (42)